Interestingly, patients pharmacologically treated for WD for less than 12 months had higher sCD163 levels than patients on long-term treatment suggesting a treatment effect with improved liver disease and reduced macrophage activation as observed in patients with chronic viral hepatitis [17, 32] or non-alcoholic fatty liver disease [33]. Here, CD163 is linked to metabolic dysfunction-associated steatotic liver disease.